Private Equity Backs Micron Technologies Management Buyout

By Gareth Macdonald

- Last updated on GMT

Related tags: Private equity

Private Equity Backs Micron Technologies Management Buyout
Private Equity Backs Micron Technologies Management Buyout
US-based particle engineering services frim Micron Technologies has been acquired in a private-equity backed management buyout. 

Malvern, Pennsylvania US-headquartered Micron provides micronization services to drug developers that want to improve the bioavailability of their active pharmaceutical ingredients (API).

The firm operates an 84,000 square foot cGMP facility in Malvern and a 19,000 square foot cGMP facility in Dartford in the UK where it employs around 100 staff and offers jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.

The management takeover – financial terms of which were not disclosed was supported by Arlington Capital Partners, the Washington DC-based private equity investment group that has been involved in a number of similar deals.

In 2007, for example, Arlington supported a management buyout by the executive team of Massachusetts-based contract manufacturing organisation (CMO) Cambridge Major Labs (CML)

Arlington sold CML to another investment group – American Capital – earlier this year​ in a deal Neal McCarthy from Fairmount Partners – the broker that represented Micron – called a “classic success story.”

McCarthy told in-Pharmatechnologist.com that: “They sold the business to American Capital recently, and it was a great success for the owners and the clients and employees, and the management will stay with the business and continue to grow it.

We represented Micron and selected Arlington partly because of their great track record in supporting growing companies, and partly because of their focus and expertise in pharmaceutical services.

He also flagged up another Arlington company – Advanced Health Media – as one to watch, suggesting that the investment group is building the regulatory compliance management systems and sales logistics services firm’s business in a similar manner.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us

Products

View more

Webinars